Discovery of Potential Best-in-Class Small Molecule Inhibitors Targeting Various KRAS Mutations for Cancers
- Introduction of Abbisko’s KRAS inhibitors franchise
- Discovery of KRAS G12D inhibitor ABSK141 with potential best-in-class oral bioavailability
- Discovery and extensive profiling of pan-KRAS inhibitor ABSK211 with potential best-in-class potency